Postmarketing Study's "End Of Usefulness" Must Be Confirmed By FDA
This article was originally published in The Tan Sheet
Executive Summary
Industry must continue to submit status reports on terminated postmarketing drug studies until FDA concurs the studies will provide no more useful information under a proposed revision to postmarketing study status annual reporting regs published in the Dec. 1 Federal Register.
You may also be interested in...
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.